Oric Pharmaceuticals (ORIC) investor relations material

Pipeline and milestones

• Rinzimetostat, an allosteric PRC2 inhibitor, entered phase III in mCRPC with an AR inhibitor; Himalayas-1 topline data are expected in H1 2028.

• Enozertinib is being developed for atypical EGFR mutations and exon 20 NSCLC; a phase III study in atypical mutations is planned for H1 2027, with exon 20 data expected mid-2027.

• The atypical-mutation phase III is planned to be randomized, enrolling over 300 patients; enozertinib 80 mg QD will be compared with physician’s choice of osimertinib or afatinib.

• Exon 20 development spans monotherapy, chemotherapy combination, and amivantamab combination; phase III could follow mid-2027 data if results show differentiation.

PRC2 evidence and MEVPRO-1

• Pfizer’s randomized phase II data showed median PFS of 14.3 months with mevrometostat plus an AR inhibitor versus about 6 months in the control arm, supporting the PRC2-plus-AR inhibitor rationale.

• Pfizer moved MEVPRO-1 primary completion from mid-2026 to Q4 2026, then to February 2027; the 600-patient blinded trial compares mevrometostat plus enzalutamide with physician’s choice of an AR inhibitor or docetaxel.

• Management viewed a major miss as very unlikely based on the broader evidence; it said a positive result could validate the mechanism, while a miss might relate to regimen, safety, or discontinuations.

• Control-arm benchmarks cited were 5–6 months for AR-inhibitor switching and 7–8 months for docetaxel; management said delayed events could reflect the treatment arm if control outcomes are as expected.

• Management said phase III blinding should reduce early discontinuations tied to patients and physicians seeing PSA results; it emphasized rPFS as the regulatory endpoint and PSA as an early, non-regulatory surrogate.

Rinzimetostat plans and differentiation

• Himalayas-1 is powered for a hazard ratio of 0.66, assuming 10.2 months in the treatment arm and 6.75 months in the control arm; more detailed MEVPRO-1 data may not arrive until mid-2027.

• A second-half program update remained planned; possible topics included Himalayas-1 progress, a second prostate phase III strategy, or incremental data from previously presented cohorts.

• Potential next phase III settings include post-AR inhibitor mCRPC and earlier mCSPC; management highlighted the larger mCSPC population and multi-year treatment duration.

• Management cited independent market research in which over 70% of physicians said they would prescribe a profile with similar efficacy and differentiated safety; it pointed to long treatment duration as a reason tolerability may matter.